Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6NOU

An scFv derived from ixekizumab

Summary for 6NOU
Entry DOI10.2210/pdb6nou/pdb
Related6NOV
DescriptorscFv derived from ixekizumab, GLYCEROL (3 entities in total)
Functional Keywordsil17, il-17, ixekizumab, scfv, antibody, immune system
Biological sourceHomo sapiens
Total number of polymer chains1
Total formula weight27987.24
Authors
Durbin, J.D.,Clawson, D.K.,Lu, F.,Tian, Y.,Lu, J.,Atwell, S. (deposition date: 2019-01-16, release date: 2019-06-19, Last modification date: 2019-08-14)
Primary citationBenschop, R.J.,Chow, C.K.,Tian, Y.,Nelson, J.,Barmettler, B.,Atwell, S.,Clawson, D.,Chai, Q.,Jones, B.,Fitchett, J.,Torgerson, S.,Ji, Y.,Bina, H.,Hu, N.,Ghanem, M.,Manetta, J.,Wroblewski, V.J.,Lu, J.,Allan, B.W.
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Mabs, 11:1175-1190, 2019
Cited by
PubMed: 31181988
DOI: 10.1080/19420862.2019.1624463
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.914 Å)
Structure validation

217705

数据于2024-03-27公开中

PDB statisticsPDBj update infoContact PDBjnumon